- Home
- DBI vs TARA Comparison
DBI vs TARA Comparison
Compare DBI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- TARA
- Stock Information
- Founded
- DBI 1991
- TARA N/A
- Country
- DBI United States
- TARA United States
- Employees
- DBI N/A
- TARA N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBI Consumer Discretionary
- TARA Health Care
- Exchange
- DBI Nasdaq
- TARA Nasdaq
- Market Cap
- DBI 138.7M
- TARA 220.7M
- IPO Year
- DBI 1991
- TARA N/A
- Fundamental
- Price
- DBI $3.62
- TARA $5.37
- Analyst Decision
- DBI Hold
- TARA Strong Buy
- Analyst Count
- DBI 2
- TARA 6
- Target Price
- DBI $4.50
- TARA $19.80
- AVG Volume (30 Days)
- DBI 670.2K
- TARA 894.9K
- Earning Date
- DBI 12-09-2025
- TARA 11-11-2025
- Dividend Yield
- DBI 5.95%
- TARA N/A
- EPS Growth
- DBI N/A
- TARA N/A
- EPS
- DBI N/A
- TARA N/A
- Revenue
- DBI $2,917,437,000.00
- TARA N/A
- Revenue This Year
- DBI N/A
- TARA N/A
- Revenue Next Year
- DBI $2.53
- TARA N/A
- P/E Ratio
- DBI N/A
- TARA N/A
- Revenue Growth
- DBI N/A
- TARA N/A
- 52 Week Low
- DBI $2.18
- TARA $1.77
- 52 Week High
- DBI $6.39
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- DBI 50.43
- TARA 65.01
- Support Level
- DBI $3.35
- TARA $5.45
- Resistance Level
- DBI $3.61
- TARA $5.92
- Average True Range (ATR)
- DBI 0.18
- TARA 0.39
- MACD
- DBI 0.01
- TARA 0.00
- Stochastic Oscillator
- DBI 84.17
- TARA 69.51
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).